Consider shorting quantum computing stocks like IonQ (IONQ) and D-Wave (QBTS), which are viewed as high-conviction shorts with no viable business models. For a long-term bullish opportunity, Spruce Biosciences (SPRB) is seen as a deeply undervalued biotech company with a potential path to a $1 billion market cap. This significant upside for SPRB could translate to a potential share price of $700, though this is dependent on future FDA approvals. It is also advised to avoid or short companies with perceived flawed business models, such as Open Door (OPEN). Lastly, avoid betting against Tesla (TSLA), as shorting the stock is considered a highly risky proposition.

Quantum Computing Sector (IONQ, RGTI, QBTS)

• The speaker expressed an overwhelmingly bearish sentiment on the entire quantum computing sector, referring to the companies as "joke stocks," "trash," and a "gigantic short."
• He believes these companies lack a viable business model or any real-world commercial applications, stating, "a cool magic trick like Shor's algorithm is not a business."
• He is actively shorting these stocks and has been "piling back into quantum shorts," even while acknowledging that the trade has caused him to lose "millions of dollars" so far.
• His conviction is extremely high, stating his pain threshold is "sort of infinite" and he will "keep adding to the trade" as long as he can remain solvent.
• Specific companies mentioned as shorts include IonQ (IONQ) and D-Wave (QBTS), which he called the "crumbiest stock of all these." He also mentioned shorting "Mergetti," which is likely a reference to Rigetti Computing (RGTI).

Takeaways

• Sentiment: Very Bearish.
• Actionable Insight: The speaker is making a high-conviction bet against the entire quantum computing sector. He believes these companies are fundamentally worthless and that their stock prices will eventually collapse. This is a very high-risk trade, as he himself admits to being early and sustaining significant losses. Investors considering this trade should be aware of the high costs of shorting (borrow fees) and the risk of a "short squeeze" where prices continue to rise.

Spruce Biosciences (SPRB)

• The speaker had a massive gain on the stock, calling it a "quick 7x" after he bought a position and publicly tweeted about it.
• The company is developing an enzyme replacement therapy for Sanfilippo B, a rare lysosomal storage disease.
• Even after a large run-up to a $140 million market cap, the speaker believes it is "still really cheap" and "tantalizing." He bought more shares during the stream on a pullback.
• Potential Valuation: He believes the company could achieve $200 million in revenue, which would make a $1 billion market cap "very reasonable." He mentioned this could equate to a share price of $700, based on his share count calculation.
• Risk Factor: He mentioned a potential risk where the FDA (BLA - Biologics License Application) could reject the drug based on manufacturing issues. However, he notes that if no further clinical trials are required, "you could easily see the stock double" even with that setback.

Takeaways

• Sentiment: Very Bullish.
• Actionable Insight: The speaker sees significant long-term upside in SPRB, viewing it as a deeply undervalued rare disease biotech company that Wall Street has overlooked. He suggests that investors who buy the stock may need to "hold on to it for a little while." The potential for a $1 billion market cap represents a substantial increase from its valuation at the time of the stream. Investors should be aware of the binary risk associated with the FDA approval process.

Short-Term Trading Signals (Using "PRT" Tool)

The speaker used a proprietary quantitative trading tool he developed (named "PRT" and "PAT") to generate and execute several short-term trades during the stream. These trades are based on pattern recognition in minute-by-minute price data and are intended to be held for very short periods (e.g., "get out within 10 minutes").

• Bearish Signals (Shorts):
  • Microchip (MCHP)
  • Rocket Lab (RKLB)
  • Pinduoduo (PDD)
  • Sprouts Farmer's Market (SFM)
  • Caterpillar (CAT) (Initially signaled long, then short)
• Bullish Signals (Longs):
  • Molina Healthcare (MOH)
  • Cummins (CMI) (Signal later reversed to sell)
  • Intel (INTC)

Takeaways

• Sentiment: Mixed, based on specific real-time signals.
• Actionable Insight: These are not long-term investment ideas but rather examples of a high-frequency, quantitative trading strategy. The speaker is using a tool to identify statistical arbitrage opportunities that last for minutes, not days or weeks. This style of trading is extremely difficult for the average investor to replicate and carries a high degree of risk.

Open Door (OPEN)

• The speaker's sentiment on the company is bearish.
• He mentioned that he previously owned the stock, "made a quick buck and got out."
• He believes it is a "terrible, terrible business model" and a "flawed business," despite liking the new CEO.

Takeaways

• Sentiment: Bearish.
• Actionable Insight: The speaker advises against investing in OPEN due to what he sees as fundamental flaws in its business model, suggesting it is not a viable long-term holding.

Cassava Sciences (SAVA)

• The speaker's sentiment is clearly bearish.
• He referenced the stock's massive run from $1 to $100, noting that he had to "ride that out really painfully," implying he was short the stock.
• He also mocked the CEO's statement "biomarkers don't lie" by immediately quipping, "but I might," casting doubt on the company's credibility.

Takeaways

• Sentiment: Bearish.
• Actionable Insight: The speaker's comments suggest a deep skepticism towards Cassava Sciences' management and scientific claims. He views it in the same category as other companies with "bad science" that he would short.

Tesla (TSLA)

• The speaker expressed a sense of caution and respect for the company's leader, Elon Musk.
• He stated that it's "really hard to bet against Elon," acknowledging that while many on Wall Street dislike him, his track record of building successful companies is undeniable.

Takeaways

• Sentiment: Neutral / Cautiously Respectful.
• Actionable Insight: While not a direct buy recommendation, the speaker warns against shorting TSLA primarily due to the "Elon factor." He implies that betting against a proven and relentless founder like Musk is a risky proposition, regardless of valuation or other metrics.

GodelTerminal (Private Investment)

• This is the speaker's own financial software company, which he is actively building.
• He presented it as a private investment opportunity for accredited investors.
• The investment minimum is $50,000.
• He is very bullish on the company's prospects, stating they laid out a "stretch goal of 5x revenue growth for this year" and that he thinks they are going to meet it.

Takeaways

• Sentiment: Very Bullish.
• Actionable Insight: This is an opportunity for accredited investors to invest in a private, early-stage financial technology startup. As with any venture investment, this carries a high degree of risk but also offers the potential for high returns if the company is successful. Interested parties were instructed to email the speaker directly.